Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Psychiatry
Published in: BMC Psychiatry 1/2016

Open Access 01-12-2016 | Research article

Is adherence therapy an effective adjunct treatment for patients with schizophrenia spectrum disorders? A systematic review and meta-analysis

Authors: Richard Gray, Daniel Bressington, Ada Ivanecka, Sheila Hardy, Martin Jones, Michael Schulz, Suparpit von Bormann, Jacquie White, Kathryn Hoehn Anderson, Wai-Tong Chien

Published in: BMC Psychiatry | Issue 1/2016

Login to get access

Abstract

Background

Poor adherence to medication in schizophrenia spectrum disorders leads to inadequate symptom control. Adherence therapy (AT) is an intervention that seeks to reduce patients’ psychiatric symptoms by enhancing treatment adherence. We aimed to systematically review the trial evidence of the effectiveness of AT on improving clinical outcomes in these patients.

Method

Systematic review and meta-analysis of published RCTs. We included studies testing AT as an adjunct intervention against treatment as usual or a comparator intervention in the general adult psychiatric population. The primary outcome of interest was improvement in psychiatric symptoms.

Results

We included six studies testing AT in schizophrenia spectrum disorders published since 2006. A meta-analysis showed AT significantly reduced psychiatric symptoms compared to usual treatment over a follow-up period of less than 1 year. We found no significant effects of AT on patients’ adherence and adherence attitudes.

Conclusions

AT is an effective adjunctive treatment for people with schizophrenia spectrum disorders.

Prospero

Appendix
Available only for authorised users
Literature
1.
Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Davis JM: Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev 2012, Issue 5. Art. No.: CD008016. DOI: 10.​1002/​14651858.​CD008016.​pub2.
2.
Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and Risk Factors for Medication Nonadherence in Patients With Schizophrenia: A Comprehensive Review of Recent Literature. J Clin Psychiatry. 2002;63(10):892–909.CrossRefPubMed
3.
Valenstein M, Ganoczy D, McCarthy JF, Myra Kim H, Lee TA, Blow FC. Antipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective review. J Clin Psychiatry. 2006;67(10):1542–50.CrossRefPubMed
4.
Novick D, Haro JM, Suarez D, Perez V, Dittmann RW, Haddad PM. Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia. Psychiatry Res. 2010;176(2–3):109–13.CrossRefPubMed
5.
Gray R, Leese M, Bindman J, Becker T, Burti L, David A, Gournay K, Kikkert M, Koeter M, Puschner B, et al. Adherence therapy for people with schizophrenia. European multicentre randomised controlled trial. Br J Psychiatry. 2006;189:508–14.CrossRefPubMed
6.
Kemp R, Kirov G, Everitt B, Hayward P, David A. Randomised controlled trial of compliance therapy. 18-month follow-up. Br J Psychiatry. 1998;172:413–9.CrossRefPubMed
7.
NICE: National Institute for Health and Clinical Excellence. Medicines adherence. Involving patients in decisions about prescribed medicines and supporting adherence. NICE clinical guideline 76. 2009.
8.
Organization WWH. Adherence to long-term therapies. Evidence for action. Geneva: World Health Organization; 2003.
9.
NICE: National Institute for Health and Care Excellence. Psychosis and schizophrenia in adults: treatment and management. NICE clinical guideline 178.; 2014.
10.
Barnes TR. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2011;25(5):567–620.CrossRefPubMed
11.
Hegedüs A, Kozel B. Does adherence therapy improve medication adherence among patients with schizophrenia? A systematic review. Int J Ment Health Nurs. 2014;23(6):490–7.CrossRefPubMed
12.
Gray R, Bressington D, Bormann S, Schulz M, Brown E, Anderson KH, Jones M. Commentary on: Hegedüs A. and Kozel B. (2014). Does adherence therapy improve medication adherence among patients with schizophrenia? A systematic review. International Journal of Mental Health Nursing, doi: 10.​1111/​inm.​12089. Int J Ment Health Nurs. 2015;24(4):370–2.CrossRefPubMed
13.
Haynes RB, McDonald H, Garg AX, Montague P: Interventions for helping patients to follow prescriptions for medications. Cochrane Database Syst Rev 2002, (2)CD000011.
14.
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–9. W264.CrossRefPubMed
15.
American Psychiatric Association [APA] (1998). Diagnostic and statistical manual of mental disorders (4th ed., text rev.). Washington, DC: Author.
16.
Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savović J, Schulz KF, Weeks L, Sterne JAC. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.CrossRefPubMedPubMedCentral
17.
RevMan. Review Manager (RevMan) [Computer programme] Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration; 2014.
18.
Chien WT, Mui JHC, Cheung EFC, Gray R. Effects of motivational interviewing-based adherence therapy for schizophrenia spectrum disorders: a randomized controlled trial. Trials. 2015;16:270.CrossRefPubMedPubMedCentral
19.
Anderson KH, Ford S, Robson D, Cassis J, Rodrigues C, Gray R. An exploratory, randomized controlled trial of adherence therapy for people with schizophrenia. Int J Ment Health Nurs. 2010;19(5):340–9.CrossRefPubMed
20.
Schulz M, Gray R, Spiekermann A, Abderhalden C, Behrens J, Driessen M. Adherence therapy following an acute episode of schizophrenia: A multi-centre randomised controlled trial. Schizophr Res. 2013;146(1–3):59–63.CrossRefPubMed
21.
Maneesakorn S, Robson D, Gournay K, Gray R. An RCT of adherence therapy for people with schizophrenia in Chiang Mai, Thailand. J Clin Nurs. 2007;16(7):1302–12.CrossRefPubMed
22.
Council MR. A framework for the development and evaluation of RCTs for complex interventions to improve health. London: Medical Research Council (MRC); 2000.
23.
Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia. Schizophr Bull. 1987;13(2):261–76.CrossRefPubMed
24.
Ventura J, Green MF, Shaner A, Liberman RP. Training and quality assurance with the Brief Psychiatric Rating Scale: ‘The drift busters’. Int J Methods Psychiatr Res. 1993;3(4):221–44.
25.
26.
von Bormann S, Robson D, Gray R. Adherence therapy following acute exacerbation of schizophrenia: A randomised controlled trial in Thailand. Int J Soc Psychiatry. 2015;61(1):3–9.CrossRef
27.
Hogan TP, Awad AG, Eastwood MR. A self report scale predictive of drug compliance in schizophrenics: reliability and discriminative ability. Psychol Med. 1983;13(1):177–83.CrossRefPubMed
28.
Voruganti LN, Awad AG. Personal evaluation of transitions in treatment (PETiT):a scale to measure subjective aspects of antipsychotic drug therapy in schizophrenia. Schizophr Res. 2002;56(1–2):37–46.CrossRefPubMed
29.
McEvoy JP, Apperson LJ, Appelbaum PS, Ortlip P, Brecosky J, Hammill K, Geller JL, Roth L. Insight in schizophrenia. Its relationship to acute psychopathology. J Nerv Ment Dis. 1989;177(1):43–7.CrossRefPubMed
30.
Staring AB, Gaag M, Koopmans GT, Selten JP, Beveren JM, Hengeveld MW, Loonen AJ, Mulder CL. Treatment adherence therapy in people with psychotic disorders: randomised controlled trial. Br J Psychiatry. 2010;197(6):448–55.CrossRefPubMed
31.
Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24(1):67–74.CrossRefPubMed
32.
Thompson K, Kulkarni J, Sergejew AA. Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. Schizophr Res. 2000;42(3):241–7.CrossRefPubMed
33.
Jeffery RA, Navarro T, Wilczynski NL, Iserman EC, Keepanasseril A, Sivaramalingam B, Agoritsas T, Haynes RB. Adherence measurement and patient recruitment methods are poor in intervention trials to improve patient adherence. J Clin Epidemiol. 2014;67(10):1076–82.CrossRefPubMed
34.
Brown E, Gray R, Jones M, Whitfield S. Effectiveness of adherence therapy in patients with early psychosis: A mirror image study. Int J Ment Health Nurs. 2013;22(1):24–34.CrossRefPubMed
35.
Cavezza C, Aurora M, Ogloff JRP. The effects of an adherence therapy approach in a secure forensic hospital: a randomised controlled trial. J Forensic Psychiatry Psychol. 2013;24(4):458–78.CrossRef
36.
Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean? Schizophr Res. 2005;79:231–8.CrossRefPubMed
37.
Kikkert MJ, Barbui C, Koeter MW, David AS, Leese M, Tansella M, Gieler A, Puschner B, Schene AH. Assessment of medication adherence in patients with schizophrenia: the Achilles heel of adherence research. J Nerv Ment Dis. 2008;196(4):274–81.CrossRefPubMed
38.
39.
Maneesakorn S. A randomised controlled trial of adherence therapy for people with schizophrenia in Thailand [PhD thesis]. London: King’s College London; 2008.
Metadata
Title
Is adherence therapy an effective adjunct treatment for patients with schizophrenia spectrum disorders? A systematic review and meta-analysis
Authors
Richard Gray
Daniel Bressington
Ada Ivanecka
Sheila Hardy
Martin Jones
Michael Schulz
Suparpit von Bormann
Jacquie White
Kathryn Hoehn Anderson
Wai-Tong Chien
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Psychiatry / Issue 1/2016
Electronic ISSN: 1471-244X
DOI
https://doi.org/10.1186/s12888-016-0801-1

Other articles of this Issue 1/2016

BMC Psychiatry 1/2016 Go to the issue

Research article

Results of a pilot cluster randomised trial of the use of a Medication Review Tool for people taking antipsychotic medication

Research article

Patient preference in psychological treatment and associations with self-reported outcome: national cross-sectional survey in England and Wales

Research article

The theoretical and practical determination of clinical cut-offs for the British Sign Language versions of PHQ-9 and GAD-7

Research article

Sexual orientation and symptoms of common mental disorder or low wellbeing: combined meta-analysis of 12 UK population health surveys

Research article

How size matters: exploring the association between quality of mental health services and catchment area size

Study protocol

An Internet-based treatment for flying phobia (NO-FEAR Airlines): study protocol for a randomized controlled trial